International perspectives on treating advanced renal cell carcinoma

Ryuta Tanimoto, MD
Department of Urology, Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania, USA

Referring to the article published on pp. 7798-7804 in this issue

Ninomiya et al 3 showed the importance of relative dose intensity (RDI) on targeted anticancer agents, especially sunitinib, and furthermore aggressive management of adverse events helped to maintain RDI that contributed to prolong the overall survival.

References